MTS-201
/ METiS TechBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 23, 2024
A Randomised, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MTS-201 in Healthy Volunteers and MTS-201 and Multiple Ascending Doses of MTS-201 in Combination with Sitagliptin in Obese, Otherwise Healthy Volunteers,
(ANZCTR)
- P1 | N=72 | Not yet recruiting | Sponsor: METiS Pharmaceuticals Australia Pty Ltd
New P1 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1